Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for two new non-executive employees. The Compensation Committee approved grants covering 24,375 shares of Puma common stock under the company's 2017 Employment Inducement Incentive Award Plan.
The restricted stock units will vest over three years, with one-third vesting on January 1, 2026 (first anniversary), and one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) ha annunciato l'approvazione di premi in forma di unità azionarie vincolate per due nuovi dipendenti non esecutivi. Il Comitato per la Retribuzione ha approvato concessioni relative a 24.375 azioni di azioni ordinarie Puma ai sensi del Piano di Incentivi per l'Occupazione del 2017 dell'azienda.
Le unità azionarie vincolate matureranno nel corso di tre anni, con un terzo che maturerà il 1° gennaio 2026 (primo anniversario), e un sesto che maturerà ogni sei mesi successivamente, a condizione di un'occupazione continuativa. Questi premi sono stati concessi come incentivi all'occupazione in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) anunció la aprobación de premios en forma de unidades de acciones restringidas para dos nuevos empleados no ejecutivos. El Comité de Compensación aprobó concesiones que cubren 24,375 acciones de acciones comunes de Puma bajo el Plan de Incentivos por Empleo de 2017 de la compañía.
Las unidades de acciones restringidas se consolidarán durante tres años, con un tercio consolidándose el 1 de enero de 2026 (primer aniversario), y un sexto consolidándose cada seis meses a partir de entonces, condicionado a la continuidad del empleo. Estos premios se otorgaron como incentivos de empleo cumpliendo con la Regla de Listado de Nasdaq 5635(c)(4).
푸마 생명공학(NASDAQ: PBYI)이 두 명의 새로운 비상무 임직원에 대한 유도 제한 주식 단위 수여 승인을 발표했습니다. 보상 위원회는 회사의 2017 고용 유도 인센티브 상여 계획에 따라 24,375주의 푸마 보통주에 대한 허가를 승인했습니다.
제한 주식 단위는 3년에 걸쳐 분할 수여되며, 1/3은 2026년 1월 1일(첫 번째 기념일)에, 이후 매 6개월마다 1/6이 부여되며, 계속 고용 조건을 충족해야 합니다. 이러한 상여는 Nasdaq 상장 규정 5635(c)(4)에 따라 고용 유도로 제공되었습니다.
Puma Biotechnology (NASDAQ: PBYI) a annoncé l'approbation de l'octroi d'unités d'actions restreintes pour deux nouveaux employés non exécutifs. Le Comité de Rémunération a approuvé des octrois portant sur 24 375 actions de l'action ordinaire de Puma dans le cadre du Plan d'Incentive à l'Emploi de 2017 de l'entreprise.
Les unités d'actions restreintes s'acquitteront sur trois ans, avec un tiers qui s'acquerra le 1er janvier 2026 (premier anniversaire) et un sixième tous les six mois par la suite, sous réserve d'un emploi continu. Ces récompenses ont été attribuées comme incitations à l'emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) gab die Genehmigung von Anreizen in Form von eingeschränkten Aktienoptionen für zwei neue nicht-executive Mitarbeiter bekannt. Der Vergütungsausschuss genehmigte die Vergabe von 24.375 Aktien des Puma-Stammkapitals gemäß dem Beschäftigungsanreizplan des Unternehmens von 2017.
Die eingeschränkten Aktienoptionen werden über einen Zeitraum von drei Jahren fällig, wobei ein Drittel am 1. Januar 2026 (erster Jahrestag) und ein Sechstel danach alle sechs Monate fällig wird, abhängig von einer fortgesetzten Anstellung. Diese Auszeichnungen wurden als Beschäftigungsanreize im Einklang mit der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- Stock-based compensation aligns employee interests with shareholders
- 24,375 new shares will cause minor shareholder dilution
The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award’s vesting commencement date, January 1, 2025, and one-sixth of the shares underlying each award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250103273128/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Source: Puma Biotechnology, Inc.
FAQ
How many shares were granted in PBYI's January 2025 inducement awards?
What is the vesting schedule for PBYI's January 2025 inducement awards?
How many new employees received PBYI's January 2025 inducement awards?
Under which plan were PBYI's January 2025 inducement awards granted?
